Trends in HeartMate 3: What we know so far.
J Card Surg
; 35(1): 180-187, 2020 Jan.
Article
em En
| MEDLINE
| ID: mdl-31692113
ABSTRACT
BACKGROUND:
The HeartMate 3 left ventricular assist device (LVAD) is a novel, intrapericardial, centrifugal-flow pump with a fully magnetically-levitated rotor designed to provide hemodynamic support in patients with end-stage heart failure. Unique aspects of this LVAD have allowed for improved hemocompatibility and the development of minimally-invasive implantation techniques.METHODS:
The PubMed, EMBASE, and Google Scholar databases were searched for publications relating to the HeartMate 3 device, with a focus on hemocompatibility related outcomes, anticoagulation management, and surgical techniques.RESULTS:
Nine articles analyzing hemocompatibility related outcomes from two clinical trials, two clinical studies, and one registry series were identified.CONCLUSION:
HeartMate 3 has reduced the rate of disabling stroke and pump thrombosis. However, despite increased hemocompatibility due to specialized design features, the residual risk of both surgical, and gastrointestinal bleeding remains a major adverse outcome. Different anticoagulation management and surgical techniques have been evaluated to address the remaining complications.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Coração Auxiliar
Tipo de estudo:
Systematic_reviews
Limite:
Humans
Idioma:
En
Revista:
J Card Surg
Assunto da revista:
CARDIOLOGIA
Ano de publicação:
2020
Tipo de documento:
Article